Due to the lack of systematic insights into an unsystematic selection of data and the lack of many oncology alliances, all the most valuable information, namely patents, trials, investments, and collaborations, is hidden in disorganized sources, including press announcements, PDF documents, or the bases of publications.
Sparse Strategic Comparisons Across Firms
Investors must compare themselves or find partners through mechanistic, scientific studies or R&D metrics.
Barricades of Mechanically Conducted Studies
The analyst’s responsibilities are too high for real-time monitoring and quick insight, especially in the case of a fast-moving target such as BioNTech.
